by Symmetron | Jan 17, 2019
Idiopathic Pulmonary Fibrosis  A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK PharmacoEconomics. 2017 Apr;35(4):479-491 Authors Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A Process \ An...
Recent Comments